Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Apr 30;13(2):11.
doi: 10.21037/atm-25-40. Epub 2025 Apr 29.

Promising results with the daily oral small molecule lipoprotein(a) inhibitor, muvalaplin, in high-risk cardiovascular patients with elevated lipoprotein(a) levels

Alpo Vuorio  1   2 , Petri T Kovanen  3 , Frederick Raal  4
Affiliations
Editorial

Promising results with the daily oral small molecule lipoprotein(a) inhibitor, muvalaplin, in high-risk cardiovascular patients with elevated lipoprotein(a) levels

Alpo Vuorio et al. Ann Transl Med. .
No abstract available

Keywords: Lipoprotein(a) [Lp(a)]; atherosclerotic cardiovascular disease (ASCVD); low-density lipoprotein cholesterol (LDL-C); muvalaplin; small molecule Lp(a) inhibitors.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-25-40/coif). A.V. has received consultancy fees from Amgen and Novartis. P.T.K. has received consultancy fees, lecture honoraria, and/or travel fees from Amgen, Novartis, Raisio Group, Amarin and Sanofi. F.R. has received research grants, honoraria, or consulting fees for professional input and/or lectures from Sanofi, Regeneron, Amgen, Novartis and LIB Therapeutics. The authors have no other conflicts of interest to declare.

Comment on

References

    1. Kraft HG, Menzel HJ, Hoppichler F, et al. Changes of genetic apolipoprotein phenotypes caused by liver transplantation. Implications for apolipoprotein synthesis. J Clin Invest 1989;83:137-42. 10.1172/JCI113849 - DOI - PMC - PubMed
    1. McLean JW, Tomlinson JE, Kuang WJ, et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987;330:132-7. 10.1038/330132a0 - DOI - PubMed
    1. Volgman AS, Koschinsky ML, Mehta A, et al. Genetics and Pathophysiological Mechanisms of Lipoprotein(a)-Associated Cardiovascular Risk. J Am Heart Assoc 2024;13:e033654. 10.1161/JAHA.123.033654 - DOI - PMC - PubMed
    1. Doherty S, Hernandez S, Rikhi R, et al. Lipoprotein(a) as a Causal Risk Factor for Cardiovascular Disease. Curr Cardiovasc Risk Rep 2025;19:8. 10.1007/s12170-025-00760-1 - DOI - PMC - PubMed
    1. Greco A, Finocchiaro S, Spagnolo M, et al. Lipoprotein(a) as a Pharmacological Target: Premises, Promises, and Prospects. Circulation 2025;151:400-15. 10.1161/CIRCULATIONAHA.124.069210 - DOI - PubMed

LinkOut - more resources